With Pfizer’s stock down sharply, an activist investor is pushing for CEO Albert Bourla to improve performance.

Barely three years since its coronavirus vaccine helped stem the pandemic, Pfizer’s stock has lost 50 percent of its value ...

Pfizer appointed a former chief executive officer at Vanguard, the drug giant's biggest investor, to its board on Tuesday as ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

As a long-term holding, Pfizer should benefit from demographic trends driving increased healthcare spending globally. The ...

As the fourth quarter of 2024 settles in, the narrative surrounding stocks on Wall Street is starting to shift.

The activist investment firm Starboard Value has launched a proxy fight again Pfizer, questioning the company’s management ...

Former Pfizer CEO Ian Read and ex-CFO Frank D'Amelio said they will not be involved with activist investor Starboard Value, ...

Fintel reports that on October 17, 2024, Bernstein initiated coverage of Pfizer (NYSE:PFE) with a Market Perform ...

Big Pharma is sticking to the recent molecular glue investment trend, with Pfizer now the latest major drugmaker to get in on ...

With valuations growing across the stock market and the biopharma sector, it's only natural for value-sensitive investors to ...

Merck’s investigational antibody clesrovimab demonstrated more than 60% effectiveness in reducing some types of respiratory ...